Actualités Australian Clinical Labs Limited - ACL | Actions Australian Stock Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

Alchemia Limited slammed 53%: Is the stock a buy?

http://www.fool.com.au/2015/05/29/alchemia-limited-slammed-53-is-the-stock-a-buy/

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer

Alchemia Limited (ASX:ACL), today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug...

UPDATE: Dr Reddy's Gets US OK For Generic Anticlotting Injection

Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received U.S. regulatory approval to launch a copy of GlaxoSmithKline PLC's (GSK...

Dr. Reddy’s Announces the USFDA Approval of Fondaparinux Sodium Injection

Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr. Reddy’s has...

Dr Reddy's Gets US OK To Sell Generic Injection To Prevent Blood Clots

Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received final approval from the U.S. Food and Drug Administration to sell a...

Alchemia to Present at Cowen and Company 31st Annual Health Care Conference

Alchemia Limited (ASX: ACL) announced today that Pete Smith, Chief Executive Officer, is scheduled to present a corporate update...

Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration

Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy’s Limited for marketing fondaparinux sodium for injection...

Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer

Alchemia’s (ASX: ACL) subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research...

Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology

Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an...

CORRECT: Alcon 3Q Profit Down 18%, Raises 2009 Earnings View

("Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time," published at 6:12 p.m. EDT, incorrectly included a tax benefit for the latest...

Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time

Alcon Inc.'s (ACL) third-quarter profit dropped 18% as foreign-exchange rates took a toll, but the eye-care products giant again raised its 2009...

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

-- Alcon takes over development of POT-4 as a treatment for patients with age-related macular degeneration -- Deal provides path for Alcon to...

Novartis veut empêcher une baisse globale de ses ventes

ZURICH (Dow Jones)--Le laboratoire pharmaceutique suisse Novartis AG (NVS) - qui devra faire face à la concurrence de médicaments...

= Novartis: Le RN stagne au T3; relève sa prévision de CA 2009

ZURICH (Dow Jones)--Novartis AG (NVS) a relevé jeudi sa prévision de chiffre d'affaires pour 2009, malgré un...

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference

Presentation to be Webcast on September 29, 2009 EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-AMEX:...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Australian Clinical Labs Limited (ACL)

Outils de qualité professionnelle, pour des investisseurs individuels.

Australian Clinical Labs Limited (ACL) Actualités

Alchemia Limited slammed 53%: Is the stock a buy?

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer

UPDATE: Dr Reddy's Gets US OK For Generic Anticlotting Injection

Dr. Reddy’s Announces the USFDA Approval of Fondaparinux Sodium Injection

Dr Reddy's Gets US OK To Sell Generic Injection To Prevent Blood Clots

Alchemia to Present at Cowen and Company 31st Annual Health Care Conference

Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration

Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer

Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology

CORRECT: Alcon 3Q Profit Down 18%, Raises 2009 Earnings View

Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

Novartis veut empêcher une baisse globale de ses ventes

= Novartis: Le RN stagne au T3; relève sa prévision de CA 2009

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Australian Clinical Labs Limited (ACL)

Outils de qualité professionnelle, pour des investisseurs individuels.

Australian Clinical Labs Limited (ACL) Actualités

Alchemia Limited slammed 53%: Is the stock a buy?

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer

UPDATE: Dr Reddy's Gets US OK For Generic Anticlotting Injection

Dr. Reddy’s Announces the USFDA Approval of Fondaparinux Sodium Injection

Dr Reddy's Gets US OK To Sell Generic Injection To Prevent Blood Clots

Alchemia to Present at Cowen and Company 31st Annual Health Care Conference

Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration

Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer

Emisphere Technologies and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen® Technology

CORRECT: Alcon 3Q Profit Down 18%, Raises 2009 Earnings View

Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

Novartis veut empêcher une baisse globale de ses ventes

= Novartis: Le RN stagne au T3; relève sa prévision de CA 2009

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités